Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Dashboard
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Analytics
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
Membership Levels
By The Numbers
Roche
35 Articles Available
1
2
Can't find what you're looking for? Try our
advanced search
.
Oncology
Roche Receives CHMP Positive Opinion for New Tecentriq-based Combination Therapy as an Initial Treatment for Most Common Form of Advanced Lung Cancer
PR-M08-19-NI-004
Leadership
Changes in Roche's Board of Directors and Corporate Executive Committee
PR-M06-19-NI-008
Approval
Roche Gets New EU Approval for MabThera
PAO-M03-19-NI-027
Gene Therapy
Roche Moves into the Gene Therapy Space
PAO-M03-19-NI-006
Generics
Roche Counters Generic Competition with New Cancer Treatments
PAO-M02-19-NI-022
Companion Diagnostics
Roche to Develop Companion Diagnostic Test to Help Identify Patients Eligible for Anti-PD-1 Therapy Based on Biomarker Expression, Not Location, of Solid Tumors
PR-M12-18-NI-050
FDA Approval
FDA Approves Roche's Tecentriq in Combination with Avastin and Chemotherapy for the Initial Treatment of People with a Specific Type of Metastatic Lung Cancer
PR-M12-18-NI-041
Appointment
Roche Exec Moves to Gilead
PAO-M12-18-NI-010
Partnership
Immunocore Expands Partnership with Roche
PAO-M11-18-NI-017
Digital Health
Roche Collaborates in Digital Health
PAO-M10-18-NI-006
Blood Test
New Blood Test from Roche Detects Common Gene Mutations
PAO-M09-18-NI-022
Drug Approval
Fast Approval for Roche Drug Alecensa in China
PAO-M08-18-NI-023
FDA Approval
Roche's cobas HPV Test receives FDA approval for first-line cervical cancer screening using SurePath preservative fluid
PR-M08-18-NI-006
Antibiotic Resistance
Roche PCT assay cleared for expanded use - Important tool in antibiotic resistance crisis
PR-M07-18-NI-049
Oncology
Phase III IMpassion130 study showed Roche’s Tecentriq plus Abraxane significantly reduced the risk of disease worsening for metastatic triple negative breast cancer
PR-M07-18-NI-021
M&A
Roche and Foundation Medicine reach definitive merger agreement to accelerate broad availability of comprehensive genomic profiling in oncology
PR-M06-18-NI-073
Collaboration
Five Prime Therapeutics Announces Collaboration with Roche to Develop Companion Diagnostics for Targeted Immuno-Oncology Investigational Drug Candidates
PR-M06-18-NI-013
Clinical Data
More Positive Phase 3 Results for Roche’s Tecentriq
PAO-M05-18-NI-024
Zika Test
FDA approves additional claim for Roche cobas Zika test
PR-M05-18-NI-061
Oncology
Roche’s TECENTRIQ (Atezolizumab) Receives Priority Review
PAO-M05-18-NI-009
Strategic Partnership
Roche Expands Partnership with 4D Molecular Therapeutics to Treat Night Blindness
PAO-M05-18-NI-001
Partnership
4DMT and ROCHE Expand Ophthalmology Partnership to Develop and Commercialize Multiple AAV Gene Therapy Products
PR-M05-18-NI-014
Drug Development
Roche expands indication for cobas® EGFR Mutation Test v2 as a companion diagnostic with TAGRISSO®
PR-M04-18-NI-84
FDA
Roche receives FDA clearance for cobas® CT/NG for cobas® 6800/8800 Systems
PR-M04-18-NI-60
1
2
»
